

Subst. for form 1449/PTO				Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/789,817	
				Filing Date	02/27/2004	
				First Named Inventor	John G. Babish	
				Art Unit	1617	
				Examiner Name	Kendra D. Carter	
Sheet	1	of	2	Docket Number	068911-0074	
U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Document Number Number-Kind Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. ¹	Document Number Country Code ³ -Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁶
	B23	DE1901277	01/10/1969	Partipharin		
OTHER						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T ²
	C104	Examination Report from related EP Application No. 05723839.6, dated 1/22/10, 6 pages.				
	C105	Bolick, et al., "Lisofylline, a Novel Anti-inflammatory Compound, Protects Mesangial Cells From Hyperglycemia - and Angiotensin II-Mediated Extracellular Matrix Deposition", ENDOCRINOLOGY, Vol. 144, No. 12, Dec.2003, pages 5227-5231.				
	C106	Abdel-Salam, et al., "The Anti-Inflammatory Effects of the Phosphodiesterase Inhibitor Pentoxifylline in the Rat", PHARMACOLOGICAL RESEARCH, ENGLAND, Vol. 47, No. 4, April 2003, pages 311-340.				
Examiner Signature					Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English Language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 2231301450.